Singapore-based venture capital firm Visvires New Protein (VVNP) is investing in Israeli aquaculture startup ViAqua, reports DealStreetAsia.
No financial details were disclosed about the size of the investment.
ViAqua’s previous investors include Nutreco; Trendlines, an Israeli accelerator; and the Technion Institute of Technology.
Launched in 2014, ViAqua aims to resolve viral infections in aquaculture. It is developing an orally administrated treatment targeting White Spot Syndrome Virus.
